{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:31:03Z","timestamp":1778895063665,"version":"3.51.4"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":2980,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:p>A pilot study was performed to investigate a clinical algorithm using serum\u2010eosinophil cationic protein level (S\u2010ECP) as an objective parameter for tapering the anti\u2010inflammatory treatment in chronic childhood asthma. We studied 21 outpatient asthmatic children (6 girls and 15 boys, mean age 9\u2003yr, range 3\u201312 yr, all with initial S\u2010ECP\u2003\u2265\u200315\u2003\u00b5g\/l) over a period of 12\u2003months at monthly intervals. At each visit a short history, clinical examination, blood sample for S\u2010ECP and eosinophil count, lung function tests and drug compliance were assessed. According to the initial S\u2010ECP, patients were allocated to two anti\u2010inflammatory treatment groups: patients with S\u2010ECP between 15\u2003\u00b5g\/l and 30\u2003\u00b5g\/l were treated with Budesonide 200\u2003\u00b5g twice daily, while patients with S\u2010ECP of 30\u2003\u00b5g\/l and above received Budesonide 400\u2003\u00b5g twice daily. After this induction treatment the anti\u2010inflammatory medication was tapered at monthly intervals according to actually measured S\u2010ECP: patients with S\u2010ECP\u2003&lt;\u200315\u2003\u00b5g\/l received sodium cromoglycate (SCG) 10\u2003mg twice daily per inhalation via spacer, patients with S\u2010ECP\u2003\u2265\u200315\u2003\u00b5g\/l and &lt;\u200330\u2003\u00b5g\/l received Budesonide 200\u2003\u00b5g twice daily via spacer, and patients with S\u2010ECP\u2003\u2265\u200330\u2003\u00b5g\/l received Budesonide 400\u2003\u00b5g twice daily. Prior to inhalation of topical steroids or SCG all patients had to inhale 500\u2003\u00b5g Terbutaline twice daily for optimal bronchodilatation. The use of medication was assessed by weighing the metered dose inhaler containers each month. Our results showed a decrease in symptoms (p\u2003=\u20030.0001) and in S\u2010ECP (p\u2003=\u20030.02) and MEF50% predicted (p\u2003=\u20030.02) after the initial month of Budesonide treatment. During a total of 246\u2003months of investigation there was no need for emergency room treatment or hospital admission, and no need for oral steroids. During the whole study period there was a tendency for inhaled steroids to be more effective than SCG in reduction of markers of airway inflammation, improvement of symptoms and lung function. Inadequate use of medication was related to an increase in S\u2010ECP in all treatment groups. From this open pilot study it is concluded that a clinical algorithm including S\u2010ECP for tapering the anti\u2010inflammatory treatment may be helpful in childhood asthma. These first observations should be confirmed by a controlled long\u2010term study.<\/jats:p>","DOI":"10.1111\/j.1399-3038.2000.00079.x","type":"journal-article","created":{"date-parts":[[2010,9,20]],"date-time":"2010-09-20T15:09:50Z","timestamp":1284995390000},"page":"87-94","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti\u2010inflammatory treatment of bronchial asthma in childhood"],"prefix":"10.1111","volume":"11","author":[{"given":"Antje","family":"Prehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard A.","family":"Seger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Torresani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix H.","family":"Sennhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3038.2000.00079.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3038.2000.00079.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T12:52:02Z","timestamp":1698583922000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3038.2000.00079.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1111\/j.1399-3038.2000.00079.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3038.2000.00079.x","archive":["Portico"],"relation":{},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}